Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2135
mi
from 91732
Tampa, FL
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
University Of South Florida Medical Center
2135
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
1919
mi
from 91732
Atlanta, GA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Emory University
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2060
mi
from 91732
Augusta, GA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Medical College of Georgia
2060
mi
from 91732
Augusta, GA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
1903
mi
from 91732
Columbus, GA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Columbus Research Institute
1903
mi
from 91732
Columbus, GA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
1729
mi
from 91732
Chicago, IL
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Northwestern University PD and Movement Disorders Center
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
1332
mi
from 91732
Kansas City, KA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
University of Kansas Medical Center
1332
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2301
mi
from 91732
Baltimore, MD
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
University of Maryland Medical Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2577
mi
from 91732
Boston, MA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Boston University School of Medicine
2577
mi
from 91732
Boston, MA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2439
mi
from 91732
Albany, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Parkinson's Disease and Movement Disorders Center of Albany
2439
mi
from 91732
Albany, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2448
mi
from 91732
Manhasset, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
North Shore Medical Center
2448
mi
from 91732
Manhasset, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2432
mi
from 91732
New York, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2433
mi
from 91732
New York, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
New York University
2433
mi
from 91732
New York, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2102
mi
from 91732
Charlotte, NC
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
The Neurological Institute
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2199
mi
from 91732
Druham, NC
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Duke University Health Systems
2199
mi
from 91732
Druham, NC
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2035
mi
from 91732
Cleveland, OH
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Cleveland Clinic
2035
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
1897
mi
from 91732
Dayton, OH
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Neurology Specialists
1897
mi
from 91732
Dayton, OH
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
827
mi
from 91732
Portland, OR
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2369
mi
from 91732
Wynnewood, PA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Lankenau Medical Center
2369
mi
from 91732
Wynnewood, PA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
2562
mi
from 91732
Providence, RI
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Butler Hospital
2562
mi
from 91732
Providence, RI
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
1357
mi
from 91732
Houston, TX
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
6112
mi
from 91732
Buenos Aires,
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Hospital Español
6112
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects
Status: Enrolling
Updated:  11/8/2013
2486
mi
from 91732
New Haven, CT
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects
Status: Enrolling
Updated: 11/8/2013
Molecular Neuroimaging, LLC
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects
Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)
Status: Enrolling
Updated:  11/12/2013
2199
mi
from 91732
Durham, NC
Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects
Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)
Status: Enrolling
Updated: 11/12/2013
Duke University Health Center
2199
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Mild Cognitive Impairment in Parkinson's Disease
A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease
Status: Enrolling
Updated:  12/17/2013
2375
mi
from 91732
Philadelphia, PA
Mild Cognitive Impairment in Parkinson's Disease
A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease
Status: Enrolling
Updated: 12/17/2013
University of Pennsylvania, Ralston House
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease
Lipopolysaccharide Binding Protein as a Potential Biomarker of Parkinson's Disease
Status: Enrolling
Updated:  1/23/2014
1726
mi
from 91732
Chicago, IL
Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease
Lipopolysaccharide Binding Protein as a Potential Biomarker of Parkinson's Disease
Status: Enrolling
Updated: 1/23/2014
Rush University Medical Center
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases
Status: Enrolling
Updated:  2/6/2014
353
mi
from 91732
San Francisco, CA
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases
Status: Enrolling
Updated: 2/6/2014
San Francisco General Hospital
353
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
PET Study of Non-Motor Symptoms of Parkinson Disease
PET Study of Biochemistry and Metabolism of the CNS: Parkinson Disease
Status: Enrolling
Updated:  5/19/2014
1932
mi
from 91732
Ann Arbor, MI
PET Study of Non-Motor Symptoms of Parkinson Disease
PET Study of Biochemistry and Metabolism of the CNS: Parkinson Disease
Status: Enrolling
Updated: 5/19/2014
University of Michigan Health System
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
25
mi
from 91732
Los Angeles, CA
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
University of California at Los Angeles
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
2104
mi
from 91732
Gainesville, FL
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
University of Florida
2104
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
2578
mi
from 91732
Boston, MA
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
2035
mi
from 91732
Cleveland, OH
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
Cleveland Clinic
2035
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
827
mi
from 91732
Portland, OR
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
Status: Enrolling
Updated:  7/7/2014
2135
mi
from 91732
Tampa, FL
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
Status: Enrolling
Updated: 7/7/2014
University of South Florida
2135
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Varenicline for Gait and Balance Impairment in Parkinson Disease
Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease
Status: Enrolling
Updated:  7/15/2014
1726
mi
from 91732
Chicago, IL
Varenicline for Gait and Balance Impairment in Parkinson Disease
Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease
Status: Enrolling
Updated: 7/15/2014
Rush University Medical Center
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated:  7/17/2014
2578
mi
from 91732
Boston, MA
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated: 7/17/2014
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
25
mi
from 91732
Los Angeles, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
UCLA-University of California at Los Angeles(904)
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
356
mi
from 91732
San Francisco, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
San Francisco-University of California at San Francisco(905)
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
358
mi
from 91732
San Francisco, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Medical Center, San Francisco
358
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
25
mi
from 91732
West Los Angeles, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Greater Los Angeles Healthcare System, West LA
25
mi
from 91732
West Los Angeles, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
826
mi
from 91732
Portland, OR
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Portland-Oregon Health & science University(906)
826
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
827
mi
from 91732
Portland, OR
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Medical Center, Portland
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
2375
mi
from 91732
Philadelphia, PA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Philadelphia-University of Pennsylvania Health System(901)
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
2373
mi
from 91732
Philadelphia, PA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Medical Center, Philadelphia
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
1357
mi
from 91732
Houston, TX
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Houston-Methodist Hospital(903)
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
1357
mi
from 91732
Houston, TX
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Michael E. DeBakey VA Medical Center (152)
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
2265
mi
from 91732
Richmond, VA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Hunter Holmes McGuire VA Medical Center
2265
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
2269
mi
from 91732
Richmond, VA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Richmond-Medical college of Virginia(902)
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
CNS Uptake of Intranasal Glutathione
Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated:  1/14/2015
961
mi
from 91732
Seattle, WA
CNS Uptake of Intranasal Glutathione
Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated: 1/14/2015
Univ of Washington
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I
Status: Enrolling
Updated:  2/4/2015
1726
mi
from 91732
Chicago, IL
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I
Status: Enrolling
Updated: 2/4/2015
Rush University Medical Center
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
Status: Enrolling
Updated:  5/26/2015
218
mi
from 91732
Las Vegas, NV
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
Status: Enrolling
Updated: 5/26/2015
University of Nevada Las Vegas
218
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials